IBRX

Your connection to the $IBRX community.
Following ImmunityBio’s progress across ANKTIVA, clinical development, commercialization, and global expansion.

[IBRX @__IBRX_]

Let’s Save life and the human race. $IBRX

[IBRX @__IBRX_]

President @realDonaldTrump can make this happen and change the lives of millions of Americans with cancer. The Cancer Moonshot went nowhere with the past administration but could succeed with President Trump's decisive action today. AMERICAN FIRST.

[IBRX @__IBRX_]

$IBRX Multiply Labs and Dr. Patrick Soon-Shiong are pushing toward fully robotic biotech manufacturing.

[IBRX @__IBRX_]

So exciting to see the results of Anktiva in bladder cancer in women who tend to have higher-grade and more advanced tumors, resulting in a higher risk of recurrence and lower survival rates compared to men.
$IBRX

[IBRX @__IBRX_]

ImmunityBio $IBRX is trading at $9.03 as of 9:37 AM EDT on Sept. 23, down 2.85% from the previous close of $9.29.

Today’s range:$9.00–$9.29
Volume:859,960

A new session,another data point. We’ll keep watching the market action alongside the company’s commercialization progress.

[IBRX @__IBRX_]

@OLovikka Yes!

[IBRX @__IBRX_]

@RiftRover58 @alc2022 $IBRX we are emerging to $11

[IBRX @__IBRX_]

$IBRX is stepping into a new conversation.

Blockchain. Tokenization. Digital ownership.

IBRX Vaults is watching the evolution of biotech and finance as the Nant ecosystem explores what’s next.

The future is moving on-chain. 🔗

#IBRX #IBRXVaults #Blockchain

[IBRX @__IBRX_]

@DrPatrick The future is here. Watch this space as we launch blockchain and tokenized stocks at Nant

[IBRX @__IBRX_]

@SteveHa80206789 Thank you for the support and for helping spread the word about the science. The continued interest in ANKTIVA and the work of the ImmunityBio team is deeply appreciated. 🙏

[IBRX @__IBRX_]

@nssilly_pete Thank you for the support and for helping spread the word about the science. The continued interest in ANKTIVA and the work of the ImmunityBio team is deeply appreciated. 🙏

[IBRX @__IBRX_]

@Kalia3202 Thank you for the support and for helping spread the word about the science. The continued interest in ANKTIVA and the work of the ImmunityBio team is deeply appreciated. 🙏

[IBRX @__IBRX_]

@LT95S Thank you for the support and for helping spread the word about the science. The continued interest in ANKTIVA and the work of the ImmunityBio team is deeply appreciated. 🙏

[IBRX @__IBRX_]

@mark_thrift Appreciate you being here! What’s got your attention most right now the ANKTIVA science, the clinical pipeline, or the $IBRX story?

[IBRX @__IBRX_]

@16Grandkidsrcoo How may I help you?

[IBRX @__IBRX_]

@underwriter63 It does in a lot of ways.

[IBRX @__IBRX_]

@StevoSarduchii2 @DrPatrick @ImmunityBio Thank you.

[IBRX @__IBRX_]

@DrPatrick @ImmunityBio The science continues to drive the conversation.

At #WCLC26, new Phase 3 insights from ReQ201A-NSCLC highlight the importance of immune-cell biology, including ALC and NK cells, in NSCLC.

More research. More data. More to watch. $IBRX #ANKTIVA #WCLC26

[IBRX @__IBRX_]

ANKTIVA’s global footprint keeps expanding. The UAE authorization brought it to 5 regulatory jurisdictions and 34 countries. 🌎 $IBRX
What market do you think will be most interesting to watch next?

[IBRX @__IBRX_]

@javiertodiaynoc A major catalyst to watch. If the sBLA submission comes through, $IBRX could get very interesting. Keeping an eye on the setup. 👀